Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 10/20 | 0.58 |
| ▸ | CYSLTR2 | Q9NS75 | 9/20 | 0.58 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9714556 | 1.00 | CYSLTR1 (0.58) | CYSLTR1CYSLTR2FFAR1AKR1B1 | |
| SCHEMBL10543991 | 0.94 | CYSLTR1 (0.65) | CYSLTR1CYSLTR2FFAR1AKR1B1 | |
| SCHEMBL9829080 | 0.92 | CYSLTR1 (0.64) | CYSLTR1CYSLTR2FFAR1AKR1B1 | |
| SCHEMBL7006454 | 0.91 | CYSLTR1 (0.62) | CYSLTR1CYSLTR2FFAR1AKR1B1 | |
| SCHEMBL6090157 | 0.91 | CYSLTR1 (0.62) | CYSLTR1CYSLTR2FFAR1AKR1B1 | |
| SCHEMBL9714654 | 0.91 | CYSLTR1 (0.54) | CYSLTR1CYSLTR2 | |
| SCHEMBL9714643 | 0.91 | CYSLTR1 (0.54) | CYSLTR1CYSLTR2 | |
| SCHEMBL9714786 | 0.91 | CYSLTR1 (0.50) | CYSLTR1CYSLTR2 | |
| SCHEMBL9714794 | 0.91 | CYSLTR1 (0.50) | CYSLTR1CYSLTR2 | |
| SCHEMBL9714772 | 0.91 | CYSLTR1 (0.48) | CYSLTR1CYSLTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5166210-A | QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1992-11-24 | — | — | US | disclosed |
| US-5028615-A | Treatment of hypersensitivity | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-07-02 | — | — | US | disclosed |